- Home
- HOWL vs KPTI Comparison
HOWL vs KPTI Comparison
Compare HOWL & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOWL
- KPTI
- Stock Information
- Founded
- HOWL 2017
- KPTI 2008
- Country
- HOWL United States
- KPTI United States
- Employees
- HOWL N/A
- KPTI N/A
- Industry
- HOWL Biotechnology: Pharmaceutical Preparations
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- HOWL Health Care
- KPTI Health Care
- Exchange
- HOWL Nasdaq
- KPTI Nasdaq
- Market Cap
- HOWL 62.4M
- KPTI 66.7M
- IPO Year
- HOWL 2021
- KPTI 2013
- Fundamental
- Price
- HOWL $1.23
- KPTI $7.53
- Analyst Decision
- HOWL Strong Buy
- KPTI Strong Buy
- Analyst Count
- HOWL 3
- KPTI 5
- Target Price
- HOWL $9.00
- KPTI $61.00
- AVG Volume (30 Days)
- HOWL 241.7K
- KPTI 144.0K
- Earning Date
- HOWL 03-11-2025
- KPTI 05-07-2025
- Dividend Yield
- HOWL N/A
- KPTI N/A
- EPS Growth
- HOWL N/A
- KPTI N/A
- EPS
- HOWL N/A
- KPTI N/A
- Revenue
- HOWL $1,885,000.00
- KPTI $145,237,000.00
- Revenue This Year
- HOWL $36.45
- KPTI $4.37
- Revenue Next Year
- HOWL $296.58
- KPTI $19.07
- P/E Ratio
- HOWL N/A
- KPTI N/A
- Revenue Growth
- HOWL N/A
- KPTI N/A
- 52 Week Low
- HOWL $1.03
- KPTI $5.90
- 52 Week High
- HOWL $6.89
- KPTI $24.75
- Technical
- Relative Strength Index (RSI)
- HOWL 44.53
- KPTI 43.25
- Support Level
- HOWL $1.18
- KPTI $5.90
- Resistance Level
- HOWL $1.29
- KPTI $8.45
- Average True Range (ATR)
- HOWL 0.10
- KPTI 1.06
- MACD
- HOWL 0.00
- KPTI -0.01
- Stochastic Oscillator
- HOWL 56.10
- KPTI 36.38
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.